Related Experiment Video
Updated: Jul 30, 2026
08:27
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
Ongoing progress in the Alzheimer's disease arena.
1Prous Science, Barcelona, Spain.
Drug News & Perspectives
|August 26, 2003
Summary
This 2000 congress explored Alzheimer's disease impacts and treatments. Key discussions covered pharmacological therapies, prevention through diet, and managing behavioral disturbances for Alzheimer's patients.
Area of Science:
- Neurology
- Gerontology
- Public Health
Background:
- Alzheimer's disease presents significant medical, social, psychological, and economic challenges.
- Understanding the disease's multifaceted effects is crucial for effective management and care.
Purpose of the Study:
- To present the latest advancements in Alzheimer's disease research and treatment.
- To foster discussion on the pathophysiology, epidemiology, diagnosis, and therapeutic strategies for Alzheimer's disease.
Main Methods:
- The World Alzheimer Congress 2000 convened experts to share findings.
- Presentations covered a wide range of topics including pharmacological treatments, prevention, and behavioral management.
Main Results:
- Explored various pharmacological approaches including beta-amyloid targeted therapies, cholinergic therapies, neuroprotective agents, and hormone-based therapies.
- Highlighted the potential role of diet in Alzheimer's prevention.
- Addressed strategies for treating behavioral disturbances associated with the disease.
Conclusions:
- The congress provided a comprehensive overview of the state of Alzheimer's research and care in 2000.
- Emphasized the need for continued research into diverse treatment modalities and preventive measures for Alzheimer's disease.
Related Concept Videos
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...